ALSUntangled #79: alpha-lipoic acid.

Area of Science:

• Biochemistry
• Neuroscience
• Pharmacology

Background:

• Alpha-lipoic acid (ALA) is a naturally occurring fatty acid with antioxidant and anti-inflammatory properties.
• ALA acts as a cofactor in mitochondrial energy production, suggesting potential roles in neurodegenerative diseases.
• Preclinical studies in amyotrophic lateral sclerosis (ALS) models indicate ALA may slow motor decline and improve survival.

Purpose of the Study:

• To evaluate the potential efficacy of alpha-lipoic acid (ALA) in slowing the progression of amyotrophic lateral sclerosis (ALS).
• To review existing evidence, including preclinical data and limited human studies, on ALA's effects in ALS patients.

Main Methods:

• Review of preclinical studies demonstrating ALA's neuroprotective effects.
• Analysis of anecdotal reports and a small open-label study involving ALS patients taking ALA with other supplements.
• Identification of the lack of published clinical trials specifically on ALA in people with ALS (PALS).

Main Results:

• Preclinical ALS studies showed ALA slowed motor function decline and improved survival.
• Anecdotal reports and a small study suggested potential benefits in muscle strength, quality of life, fatigue, and mood, but confounding factors exist.
• No clinical trials have been published to date assessing ALA's efficacy in PALS.

Conclusions:

• While ALA exhibits plausible mechanisms and preclinical promise for ALS, current clinical data is insufficient for endorsement.
• Further rigorous clinical trials are required to determine the efficacy and safety of ALA in slowing ALS progression.
• Current evidence does not support the use of ALA as a standalone treatment for ALS.